{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T21:49:27Z","timestamp":1792532967934,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:00:00Z","timestamp":1720569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019155","name":"Nanjing University Medical School Affiliated Nanjing Drum Tower Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019155","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.eprac.2024.07.006","type":"journal-article","created":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T16:44:55Z","timestamp":1720975495000},"page":"943-950","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Development and Validation of a Prediction Model for Thyroid Dysfunction in Patients During Immunotherapy"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8920-6504","authenticated-orcid":false,"given":"Qian","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanqin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuetao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanmei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.eprac.2024.07.006_bib1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.36128","article-title":"Efficacy and safety associated with immune checkpoint inhibitors in unresectable hepatocellular carcinoma: a meta-analysis","volume":"4","author":"Jacome","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.eprac.2024.07.006_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.908026","article-title":"A\u00a0meta-analysis with systematic review: efficacy and safety of immune checkpoint inhibitors in patients with advanced gastric cancer","volume":"12","author":"El Helali","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.eprac.2024.07.006_bib3","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12885-023-10605-y","article-title":"Efficacy of PD-1\/PD-L1 inhibitors in gastric or gastro-oesophageal junction cancer based on clinical characteristics: a meta-analysis","volume":"23","author":"Huo","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.eprac.2024.07.006_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1010279","article-title":"Thyroid-related adverse events induced by immune checkpoint inhibitors","volume":"13","author":"Chera","year":"2022","journal-title":"Front Endocrinol"},{"issue":"9","key":"10.1016\/j.eprac.2024.07.006_bib5","doi-asserted-by":"crossref","first-page":"e3704","DOI":"10.1210\/clinem\/dgab263","article-title":"Thyroid immune-related adverse events following immune checkpoint inhibitor treatment","volume":"106","author":"Muir","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.eprac.2024.07.006_bib6","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/1759-7714.14274","article-title":"Immune checkpoint inhibitor-related adverse events in lung cancer: real-world incidence and management practices of 1905 patients in China","volume":"13","author":"Shi","year":"2022","journal-title":"Thorac Cancer"},{"issue":"2","key":"10.1016\/j.eprac.2024.07.006_bib7","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1093\/oncolo\/oyab043","article-title":"Immune checkpoint inhibitor-related new-onset thyroid dysfunction: a retrospective analysis using the US FDA adverse event reporting system","volume":"27","author":"Lu","year":"2022","journal-title":"Oncol"},{"issue":"2","key":"10.1016\/j.eprac.2024.07.006_bib8","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3803\/EnM.2020.906","article-title":"Characteristics of immune-related thyroid adverse events in patients treated with PD-1\/PD-L1 inhibitors","volume":"36","author":"Yoon","year":"2021","journal-title":"Endocrinol Metab (Seoul)"},{"key":"10.1016\/j.eprac.2024.07.006_bib9","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.3389\/fphar.2019.01671","article-title":"Organ-specific immune-related adverse events associated with immune checkpoint inhibitor monotherapy versus combination therapy in cancer: a meta-analysis of randomized controlled Trials","volume":"10","author":"Da","year":"2019","journal-title":"Front Pharmacol"},{"issue":"10","key":"10.1016\/j.eprac.2024.07.006_bib10","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eprac.2024.07.006_bib11","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s12020-023-03323-9","article-title":"Thyroid dysfunction after immune checkpoint inhibitor treatment in a single-center Chinese cohort: a retrospective study","volume":"81","author":"Wu","year":"2023","journal-title":"Endocrine"},{"issue":"11","key":"10.1016\/j.eprac.2024.07.006_bib12","doi-asserted-by":"crossref","first-page":"8993","DOI":"10.1007\/s00432-023-04792-1","article-title":"Predictors of immune checkpoint inhibitor-related adverse events in older patients with lung cancer: a prospective real-world analysis","volume":"149","author":"Gao","year":"2023","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"9","key":"10.1016\/j.eprac.2024.07.006_bib13","doi-asserted-by":"crossref","first-page":"10636","DOI":"10.1002\/cam4.5816","article-title":"Peripheral lymphocyte fluctuation as an indicator of severe immune-related adverse events in patients treated with immune checkpoint inhibitors","volume":"12","author":"Haraguchi","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.eprac.2024.07.006_bib14","article-title":"Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.eprac.2024.07.006_bib15","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jtho.2022.11.007","article-title":"Prediction of distant metastases after stereotactic body radiation therapy for early stage NSCLC: development and external validation of a multi-institutional model","volume":"18","author":"Gao","year":"2023","journal-title":"J\u00a0Thorac Oncol"},{"issue":"7","key":"10.1016\/j.eprac.2024.07.006_bib16","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1200\/JCO.21.01784","article-title":"Diet- and lifestyle-based prediction models to estimate cancer recurrence and death in patients with stage III colon cancer (CALGB 89803\/Alliance)","volume":"40","author":"Cheng","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"36","key":"10.1016\/j.eprac.2024.07.006_bib17","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.eprac.2024.07.006_bib18","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3390\/cancers15010246","article-title":"Management of endocrine and metabolic toxicities of immune-checkpoint inhibitors: from clinical studies to a real-life scenario","volume":"15","author":"Spagnolo","year":"2022","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.eprac.2024.07.006_bib19","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1210\/clinem\/dgad260","article-title":"Clinical characters and influence factors of immune checkpoint inhibitor-related thyroid dysfunction","volume":"108","author":"Zhang","year":"2023","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2024.07.006_bib20","doi-asserted-by":"crossref","first-page":"101660","DOI":"10.1016\/j.beem.2022.101660","article-title":"Immune checkpoint inhibitor-related thyroid dysfunction","volume":"36","author":"Iwama","year":"2022","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2024.07.006_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.649863","article-title":"Immune checkpoint inhibitors-related thyroid dysfunction: epidemiology, clinical presentation, possible pathogenesis, and management","volume":"12","author":"Zhan","year":"2021","journal-title":"Front Endocrinol"},{"issue":"10","key":"10.1016\/j.eprac.2024.07.006_bib22","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1089\/thy.2020.0075","article-title":"Immune checkpoint inhibitor-induced thyroiditis is associated with increased intrathyroidal T lymphocyte subpopulations","volume":"30","author":"Kotwal","year":"2020","journal-title":"Thyroid"},{"issue":"5","key":"10.1016\/j.eprac.2024.07.006_bib23","doi-asserted-by":"crossref","first-page":"e1843","DOI":"10.1210\/clinem\/dgac059","article-title":"Association of antithyroid antibodies in checkpoint inhibitor\u2013associated thyroid immune\u2013related adverse events","volume":"107","author":"Muir","year":"2022","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.eprac.2024.07.006_bib24","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s40618-019-01058-x","article-title":"Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors","volume":"42","author":"Mazarico","year":"2019","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.eprac.2024.07.006_bib25","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/cei\/uxad105","article-title":"Toxicity spectrum and risk factors for chemo-immunotherapy in locally advanced or metastatic lung cancer","volume":"214","author":"Li","year":"2023","journal-title":"Clin Exp Immunol"},{"issue":"8","key":"10.1016\/j.eprac.2024.07.006_bib26","doi-asserted-by":"crossref","first-page":"824","DOI":"10.4158\/EP-2018-0472","article-title":"Baseline tsh level is associated with risk of anti-Pd-1-Induced thyroid dysfunction","volume":"25","author":"Pollack","year":"2019","journal-title":"Endocr Pract"},{"issue":"8","key":"10.1016\/j.eprac.2024.07.006_bib27","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1007\/s40618-020-01480-6","article-title":"Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy","volume":"44","author":"Brilli","year":"2021","journal-title":"J\u00a0Endocrinol Invest"},{"issue":"1","key":"10.1016\/j.eprac.2024.07.006_bib28","doi-asserted-by":"crossref","first-page":"7005","DOI":"10.1038\/s41467-021-27303-7","article-title":"Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer","volume":"12","author":"Hinterleitner","year":"2021","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.eprac.2024.07.006_bib29","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41577-023-00834-4","article-title":"The role of platelets in immune-mediated inflammatory diseases","volume":"23","author":"Scherlinger","year":"2023","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1016\/j.eprac.2024.07.006_bib30","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCRESAHA.117.310795","article-title":"Circulating platelets as mediators of immunity, inflammation, and thrombosis","volume":"122","author":"Koupenova","year":"2018","journal-title":"Circ Res"},{"issue":"1","key":"10.1016\/j.eprac.2024.07.006_bib31","doi-asserted-by":"crossref","first-page":"9029","DOI":"10.1038\/s41598-021-88307-3","article-title":"Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors","volume":"11","author":"Michailidou","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.eprac.2024.07.006_bib32","doi-asserted-by":"crossref","DOI":"10.1177\/15330338231206705","article-title":"The predictive model construction for immune-related adverse events in non-small cell lung cancer patients receiving immunotherapy","volume":"22","author":"Gao","year":"2023","journal-title":"Technol Cancer Res Treat"},{"issue":"8","key":"10.1016\/j.eprac.2024.07.006_bib33","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1634\/theoncologist.2018-0563","article-title":"Peripheral blood markers identify risk of immune-related toxicity in advanced non-small cell lung cancer treated with immune-checkpoint inhibitors","volume":"24","author":"Pavan","year":"2019","journal-title":"Oncol"},{"issue":"11","key":"10.1016\/j.eprac.2024.07.006_bib34","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.4251\/wjgo.v15.i11.1900","article-title":"Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma","volume":"15","author":"Dharmapuri","year":"2023","journal-title":"World J Gastrointest Oncol"},{"key":"10.1016\/j.eprac.2024.07.006_bib35","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2147\/CMAR.S293200","article-title":"Peripheral blood markers associated with immune-related adverse effects in patients who had advanced non-small cell lung cancer treated with PD-1 inhibitors","volume":"13","author":"Liu","year":"2021","journal-title":"Cancer Manag Res"},{"issue":"7","key":"10.1016\/j.eprac.2024.07.006_bib36","first-page":"2105","article-title":"Peripheral blood biomarkers predict immune-related adverse events in non-small cell lung cancer patients treated with pembrolizumab: a multicenter retrospective study","volume":"12","author":"Egami","year":"2021","journal-title":"J\u00a0Cancer"},{"issue":"2","key":"10.1016\/j.eprac.2024.07.006_bib37","doi-asserted-by":"crossref","first-page":"695","DOI":"10.31557\/APJCP.2022.23.2.695","article-title":"Identifying early predictive markers for immune-related adverse events in nivolumab-treated patients with renal cell carcinoma and gastric cancer","volume":"23","author":"Takada","year":"2022","journal-title":"Asian Pac J Cancer Prev"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X24006049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X24006049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T09:56:51Z","timestamp":1727776611000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X24006049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1530891X24006049"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2024.07.006","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and Validation of a Prediction Model for Thyroid Dysfunction in Patients During Immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2024.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 AACE. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}